Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the sale, the chief financial officer directly owned 37,592 shares in the company, valued at $624,027.20. This represents a 27.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Houte Hans Van also recently made the following trade(s):
- On Thursday, April 30th, Houte Hans Van sold 2,388 shares of Nurix Therapeutics stock. The shares were sold at an average price of $16.65, for a total value of $39,760.20.
Nurix Therapeutics Stock Performance
Nurix Therapeutics stock traded down $0.33 during midday trading on Tuesday, reaching $16.60. The company’s stock had a trading volume of 1,323,024 shares, compared to its average volume of 1,129,111. Nurix Therapeutics, Inc. has a fifty-two week low of $8.19 and a fifty-two week high of $22.50. The stock’s 50 day simple moving average is $15.83 and its 200 day simple moving average is $16.08. The firm has a market capitalization of $1.72 billion, a PE ratio of -5.25 and a beta of 1.87.
Analysts Set New Price Targets
A number of research analysts have issued reports on NRIX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Nurix Therapeutics in a report on Monday, April 27th. Royal Bank Of Canada increased their target price on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, January 29th. Stifel Nicolaus increased their target price on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Finally, Morgan Stanley set a $36.00 target price on Nurix Therapeutics and gave the company an “overweight” rating in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.46.
Read Our Latest Report on NRIX
Institutional Trading of Nurix Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC lifted its holdings in shares of Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after acquiring an additional 1,190 shares during the period. Intesa Sanpaolo Wealth Management purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth about $31,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth about $33,000. Wexford Capital LP purchased a new position in shares of Nurix Therapeutics during the 3rd quarter worth about $41,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after acquiring an additional 3,475 shares during the period.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Read More
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
